Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | NHS England |
| Main Category: | Services |
| Procurement Method: | Open procedure (above threshold) |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 27 May 2022 |
| Application Deadline: | 7 February 2022 |
| Contract Start Date: | 1 May 2022 |
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award value: | £1 |
| Award decision date: | 27 April 2022 |
| Award status: | Active |
This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.
Published contracts in the last 12 months
2,046
total contracts
£179666.3m
total value
£251,986,446
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
7 February 2022
Closed
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Contract End Date: |
| 1 August 2023 |
| Contract Duration: | 1.3 years |
| Procurement ID (OCID): | ocds-b5fd17-1e540e5e-f34d-4bb0-8ea0-37b48a292799 |
| Notice Reference: | 6c3af4d4-10c7-4b77-9f21-6455ad0e5c2c-542395 |